Professor Peter Schmid is an Onkologie practitioner based in London, Vereinigtes Königreich, practising at Universidad de Navarra Teaching Hospital. They have 29+ years of clinical experience. Procedures focus on gp consultation, annual physical exam, vaccination administration, minor procedure (skin). Educated at Universidad de Navarra (MD, 2022). Serves patients in London, Vereinigtes Königreich and the surrounding area.
VERIFIED PHYSICIAN PROFILE · UPDATED MAY 2026
Über uns
Professor Peter Schmid is an internationally renowned breast cancer oncologist. He is the clinical director of the Breast Cancer Centre at St. Bartholomew's Hospital in London, and Chair in Cancer Medicine at Barts Cancer Institute, Queen Mary University London. His private practice is based at LOC Harley Street, LOC at Chelsea, the Platinum Medical Centre, the Wellington Hospital, the Harley Street Clinic and at the Princess Grace Hospital.
Professor Schmid's work is devoted to incorporating novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer. He has an interest in breast cancer from diagnosis throughout treatment to optimal recovery, and also has a particular interest in triple-negative breast cancer, young women with breast cancer, pregnancy-associated breast cancer and fertility related issues. Professor Schmid is committed to patient-centred, holistic care, tailoring treatments for individual patients using biology, personal preference and constant review of outcomes of care. He works in the context of a multidisciplinary team with breast care nurse support for patients. Professor Schmid has a strong interest in patient-doctor communication and ran a training programme for oncologists and oncology nurses for many years.
Professor Schmid's research is dedicated to improving the care of women with breast cancer by developing more effective and less toxic treatments. He runs an international clinical and translational research programme. His group is investigating a variety of novel agents that target specific pathways within cancer cells and the surrounding tissue. He is the lead investigator of several international, pivotal breast cancer studies on novel targeted therapeutics to improve the treatment of both early and late stage breast cancer. Most trials incorporate translational research endpoints to improve our understanding of molecular factors that may elucidate mechanisms of action and predictors of treatment effect; this includes a programme on the impact of the microbiome on patient outcomes. Professor Schmid is renowned internationally for his work in cancer immunotherapy. He was the lead investigator of the Impassion130 trial that evaluated atezolizumab for advanced triple-negative breast cancer and lead to the approval of the first immunotherapy strategy for patients with breast cancer, establishing a new standard of care for this disease. He was also the lead investigator of the KEYNOTE-522 trial which established the addition of the immune-checkpoint inhibitor Pembrolizumab to preoperative chemotherapy as a new standard for patients with stage II or III triple-negative breast cancer based on a nearly 40% reduction in recurrences of this aggressive subtype of breast cancer. His current research interests include cancer immune therapy combinations across all stages and subtypes of breast cancer, novel targeted agents and antibody-drug conjugates - alone or in combination - to overcome resistance, and innovative biomarker-driven trial concepts. Professor Schmid's work has been published in many journals including the New England Journal of Medicine, Lancet, Lancet Oncology, JAMA Oncology, Nature Communications and the Journal of Clinical Oncology.
In addition to his clinical and research work, Professor Schmid is committed to education, regularly lecturing locally, nationally and internationally on subjects relating to the treatment of and supportive care for breast cancer. Professor Schmid is medical director of Perci Health, a virtual care clinic, to provide access to high-quality cancer experts across multi-disciplinary fields, focused holistically on recovery from a physical, mental, social and emotional point of view.
Prof Schmid is a member of several national and international cancer organisations and research groups. He has been involved in international consensus meetings on the management of breast cancer and is co-author of international breast cancer guidelines. Professor Peter Schmid is Chair of the European Society for Medical Oncology (ESMO) breast cancer faculty.
Areas of interest
Breast cancer from early breast cancer to advanced (secondary) disease, including endocrine treatment, immunotherapy, chemotherapy and targeted treatment.
Breast cancer in young adults
Triple-negative breast cancer
Hormone-receptor positive and HER2-positive breast cancer
Hormone-resistance
Interest in holistic management of side-effects of treatment, including aspects of fertility, pregnancy, menopausal symptoms and bone health.
Works in context of multidisciplinary team with breast care nurse support for patients.
Personalised medicines and appropriate genetic testing.
Immunotherapy
Novel targeted agents and antibody-drug conjugates
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
Teilen Sie Ihre Erfahrung
— Helfen Sie anderen Patienten, den richtigen Arzt zu finden. Bewertung schreiben →
Aktuelle Bewertungen
★★★★★ ✓ Verifiziert
Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.
★★★★★ ✓ Verifiziert
Took time to listen and reviewed all my previous results. I would absolutely recommend.
★★★★☆ ✓ Verifiziert
Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.
SPECIALTIES & PROCEDURES
Professor Peter Schmid's Areas of Specialty
Each specialty below reflects the conditions and procedures Professor Peter Schmid treats, with the size of the national pool of Vereinigtes Königreich doctors offering the same care.
Onkologie
Cancer diagnosis and treatment including chemotherapy, immunotherapy, targeted therapy and survivorship care.
Medical practice in Vereinigtes Königreich is governed by country-specific licensing, professional standards, and patient-safety regulations. Practitioners listed here are registered with the relevant Vereinigtes Königreich medical authority and operate within national rules on scope of practice, prescribing rights, and continuing professional development. Care delivered in London carries the additional benefits of local language support, in-person follow-up, and direct coordination with regional hospitals and labs. A verified profile means EuroClinics has cross-checked the practitioner or clinic against an official source (national medical register, public licence database, or the practitioner themselves), and that the data shown here matches that source as of the last verification date above.
Schnelle Antworten auf die Fragen, die Patienten am häufigsten stellen. Dieselben Antworten werden über strukturierte Daten an KI-Assistenten weitergegeben.
What does Peter Schmid specialise in?
Peter Schmid specialises in Onkologie in London, GB. 29 years of clinical experience.
What conditions does Peter Schmid treat?
Peter Schmid treats conditions within Onkologie. View the full conditions-treated list on the profile.
Where does Peter Schmid practise?
Peter Schmid practises in London, GB. The profile page lists all practice addresses, phone numbers, and clinic affiliations.
What languages does Peter Schmid speak?
Peter Schmid speaks English.
How do I book an appointment with Peter Schmid?
Use the "Request a booking" button on the profile to send an appointment request. Most appointments are confirmed within 24 hours; many slots are bookable instantly.
We use essential cookies for the site to work. With your consent we also use
analytics + marketing cookies to improve EuroClinics. You can change your
choice any time on the cookies page.
